NewsPathos AI’s $237M Series E: Strategic Capital Matters More Than Valuation
Pathos AI’s $237 million Series E is only one part of a broader strategic relationship involving Bristol Myers Squibb and Tempus AI. Separate oncology and neurology agreements show why the structure around the capital may matter more than the headline valuation.